1.Richman, D., Wrin, M.T., Little, S., Petropoulos, C.J., Parkin, N.T., Whitcomb, J., and Huang, W. Methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays. US 9,841,425, issued December 12, 2017

2.Richman, D., Wrin, M.T., Little, S., Petropoulos, C.J., Parkin, N.T., Whitcomb, J., and Huang, W. Methods for determining the presence of antibodies blocking viral infection. US 9,175,355, issued November 3, 2015

3.Gupta, S., Fransen, S., Paxinos, E., and Parkin, N.T. Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs. US 8,637,252, issued January 28, 2014

4.Coakley, E. and Parkin, N. T. Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors. US 8,178,291, issued May 15, 2012.

5.Gupta, S., Fransen, S., Paxinos E., and Parkin, N. T. Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs. US 8,071,284, issued Dec. 2011.

6.Chappey, C., Petropoulos, C. J., and Parkin, N. T. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors.  US 7,993,824, issued August 2011.

7.Parkin, N. T., Paxinos, E, Chappey, C, Wrin M. T., Gamarnik, A, Petropoulos, C. J. Method for determining human immunodeficiciency virus type 1 (HIV-1) hypersusceptibility to the protease inhibitor amprenavir.  US 7,553,618, issued June 30, 2009

8.Parkin, N. T., Chappey, C., Petropoulos, C. J. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors. US 7,384,734, issued June 10, 2008

9.Richman, D., Wrin, M.T., Little, S., Petropoulos, C.J., Parkin, N.T., Whitcomb, J., and Huang, W.  Method of evaluating a patient antibody response to envelope proteins of a virus. US 7,247,439, Issued 7/24/07.

10. Petropoulos, C.J., Parkin, N.T., Whitcomb, J., and Huang, W. Methods of evaluating cell surface receptor binding of a patient derived population of viral envelope protein constructs.  US 7,235,356, issued 6/26/07.

11. Parkin, N.T. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS. US 7,186,506, issued 3/6/2007.

12. Petropoulos, C.J., Parkin, N.T., Whitcomb, J., and Huang, W. Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs.  US 7,169,551, issued 1/30/2007.

13. Parkin, N.T. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS. US 7,138,231, issued 11/21/2006.

14. Petropoulos, C.J., Parkin, N.T., Whitcomb, J., and Huang, W. Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs.  US 7,097,970, issued 8/29/2006.

15. Parkin, N.T. and Ziermann, R. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS. US 6,869,759, issued 3/22/2005.

16. Parkin, N.T. Recombinant Tryptophan Mutants of Influenza. US 6,974,686, issued December 2005

17. Parkin, N.T. and Coelingh, K.  Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation.  US 6,843,996, issued 1/18/2005.

18. Parkin, N.T. Whitcomb, J.M. and Capon, D. (CIP to Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening US 05837464ss, issued November 1998).

19. Parkin, N.T. Recombinant Tryptophan Mutants of Influenza. US 6,528,064, issued March 2003

20. Parkin, N.T. Recombinant Tryptophan Mutants of Influenza. US 6,322,967, issued November 2001.

21. Parkin, N.T. Recombinant Tryptophan Mutants of Influenza. US 6,090,391, issued July  2000.

22. Parkin, N.T. and Coelingh, K. Novel recombinant temperature sensitive mutants of influenza. US 5,690,937; issued March 1999.